Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Sponsor: Nuvation Bio Inc.
Terminated
Sponsor decision
Other terminated trials from Nuvation Bio Inc.
More terminations from Nuvation Bio Inc.
Other Advanced Breast Cancer trials with similar outcome
Listed as NCT04541225, this PHASE1 trial focuses on Advanced Breast Cancer and Advanced Breast Carcinoma and remains terminated or withdrawn. Sponsored by Nuvation Bio Inc., it has been updated 13 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Aug 2023 — Jul 2024 [monthly]
Terminated PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Nov 2022 — Aug 2023 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Oct 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 8 earlier versions
-
Jul 2022 — Oct 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2022 — Jul 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nuvation Bio Inc.
For direct contact, visit the study record on ClinicalTrials.gov .